Unveiling Swelling and Erosion Dynamics: Early Development Screening of Mirabegron Extended Release Tablets
- PMID: 39604660
- DOI: 10.1208/s12249-024-02994-5
Unveiling Swelling and Erosion Dynamics: Early Development Screening of Mirabegron Extended Release Tablets
Abstract
Although the development of extended release (ER) matrices has been extensively investigated, understanding the most appropriate mechanism of drug release to achieve the desired release remains a cost- and time-consuming challenge in the early stages of formulation development. This study aimed to investigate the early stage of developing ER hydrophilic matrix tablets containing mirabegron as a model drug, focusing on the effects of polymer type, diluent type, and polymer amount on critical quality attributes (CQAs), namely, tablet swelling and erosion behavior. A full factorial design was employed to explore the interactions of control factors through multivariate regression analysis, emphasizing the application of quality by design (QbD) principles. The swelling and erosion performances of 72 formulations were evaluated. The swelling data were fitted to the Vergnaud model. Finally, in vitro drug release profiles were investigated for four of the formulations studied. The polymer type, diluent type, and polymer amount had distinct effects on the swelling and erosion behavior of the ER matrix tablets. Compared with those with isomalt (G720) or dextrate (DXT), formulations with polyethylene glycol 8000 (P8000) consistently exhibited greater swelling. Additionally, higher molecular weight was correlated with increased swelling within the same polymer type. Hydroxypropylmethylcellulose (HPMC) and polyethylene oxide (PEO)-based formulations showed higher swelling rates, while polyvinyl alcohol (PVA-80) displayed the highest erosion percentage. The findings highlight the significance of incorporating early-stage screening designs to maximize efficiency and optimize time and resource. This approach enables the development of a comprehensive understanding of drug release mechanisms from ER matrix tablets.
Keywords: erosion; extended release matrix tablets; formulation screening; quality by design; swelling.
© 2024. The Author(s).
Conflict of interest statement
Declarations. Conflict of Interest: The authors declare no conflicts of interest.
References
-
- Lee HJ, Kim JY, Park SH, Rhee YS, Park CW, Park ES. Controlled-release oral dosage forms containing nimodipine solid dispersion and hydrophilic carriers. J Drug Deliv Sci Technol. 2017;37:28–37. https://doi.org/10.1016/j.jddst.2016.11.001 . - DOI
-
- Nigusse B, Gebre-Mariam T, Belete A. Design, development and optimization of sustained release floating, bioadhesive and swellable matrix tablet of ranitidine hydrochloride. PLoS ONE. 2021;16(6):e0253391. https://doi.org/10.1371/journal.pone.0253391 . - DOI - PubMed - PMC
-
- Khan KA, Zizzadoro C, Di Cerbo A, Pugliese N, Khan GM, Ghazanfar S, et al. Preparation and in Vitro evaluation of controlled-release matrices of losartan potassium using Ethocel Grade 10 and Carbopol 934P NF as rate-controlling polymers. Polymers. 2022;14(15):2993. https://doi.org/10.3390/polym14152993 . - DOI - PubMed - PMC
-
- Timmins P, Pygall S, Melia CD. Hydrophilic matrix dosage forms: definitions, General attributes, and the evolution of clinical utilization. In: Timmins P, Pygall S, Melia CD, editors. Hydrophilic matrix tablets for oral controlled release. New York Heidelberg Dordrecht London: Springer; 2014. pp. 1–16. - DOI
-
- Colombo P, Bettini R, Peppas NA. Observation of swelling process and diffusion front position during swelling in hydroxypropyl methyl cellulose (HPMC) matrices containing a soluble drug. J Control Release. 1999;61(1–2):83–91. https://doi.org/10.1016/s0168-3659(99)00104-2 . - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous